These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24620802)

  • 1. Measuring soluble biomarkers in clinical trials: do tiered approaches to the analysis and validation of assays provide an answer to the fit-for-purpose challenge?
    Hucker R; Watson C; James I; Vincent S; Muirhead D
    Bioanalysis; 2014 Mar; 6(5):605-9. PubMed ID: 24620802
    [No Abstract]   [Full Text] [Related]  

  • 2. Mismanaged measures.
    Nature; 2008 Apr; 452(7187):504. PubMed ID: 18385690
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug markers questioned.
    Ledford H
    Nature; 2008 Apr; 452(7187):510-1. PubMed ID: 18385695
    [No Abstract]   [Full Text] [Related]  

  • 4. Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers.
    Sargent DJ; Mandrekar SJ
    Clin Trials; 2013 Oct; 10(5):647-52. PubMed ID: 23983158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inexplicable oversight and a misconception in research.
    Ingenbleek Y; Cynober L
    J Nutr Health Aging; 2005; 9(3):199. PubMed ID: 15864401
    [No Abstract]   [Full Text] [Related]  

  • 6. [Biological markers: utilization in drug development and approval].
    Gueyffier F; Dib M; Boissel JP
    Therapie; 2001; 56(4):355-61. PubMed ID: 11677852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prototypical process for creating evidentiary standards for biomarkers and diagnostics.
    Altar CA; Amakye D; Bounos D; Bloom J; Clack G; Dean R; Devanarayan V; Fu D; Furlong S; Hinman L; Girman C; Lathia C; Lesko L; Madani S; Mayne J; Meyer J; Raunig D; Sager P; Williams SA; Wong P; Zerba K
    Clin Pharmacol Ther; 2008 Feb; 83(2):368-71. PubMed ID: 18091762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker method validation in anticancer drug development.
    Cummings J; Ward TH; Greystoke A; Ranson M; Dive C
    Br J Pharmacol; 2008 Feb; 153(4):646-56. PubMed ID: 17876307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From research to regulated: challenges in transferring methods.
    Chowdhury F; Williams A
    Bioanalysis; 2009 May; 1(2):285-91. PubMed ID: 21083167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research and standardization in Alzheimer's trials: reaching international consensus.
    Carrillo MC; Rowe CC; Szoeke C; Masters CL; Ames D; O'Meara T; Macaulay SL; Milner A; Ellis KA; Maruff P; Rainey-Smith SR; Martins RN; Bain LJ; Head RJ;
    Alzheimers Dement; 2013 Mar; 9(2):160-8. PubMed ID: 23266004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiered approach revisited: introducing stage-appropriate or assay-appropriate scientific validation.
    Timmerman P
    Bioanalysis; 2014 Mar; 6(5):599-604. PubMed ID: 24620801
    [No Abstract]   [Full Text] [Related]  

  • 12. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
    D'Haens G; Sandborn WJ; Feagan BG; Geboes K; Hanauer SB; Irvine EJ; Lémann M; Marteau P; Rutgeerts P; Schölmerich J; Sutherland LR
    Gastroenterology; 2007 Feb; 132(2):763-86. PubMed ID: 17258735
    [No Abstract]   [Full Text] [Related]  

  • 13. Minimum data set for nutritional intervention studies in the elderly IAG/ IANA task force consensus.
    Salva A; Corman B; Andrieu S; Salas J; Porras C; Vellas B;
    J Nutr Health Aging; 2004; 8(4):202-6. PubMed ID: 15316582
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy assessment in paediatric studies.
    Wang S; Laitinen-Parkkonen P
    Handb Exp Pharmacol; 2011; 205():149-68. PubMed ID: 21882110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Related causal frameworks for surrogate outcomes.
    Joffe MM; Greene T
    Biometrics; 2009 Jun; 65(2):530-8. PubMed ID: 18759836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use and abuse of surrogate endpoints in clinical research in transfusion medicine.
    Arnold DM; Lim W
    Transfusion; 2008 Aug; 48(8):1547-9. PubMed ID: 18507746
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategic approach to fit-for-purpose biomarkers in drug development.
    Wagner JA
    Annu Rev Pharmacol Toxicol; 2008; 48():631-51. PubMed ID: 17937595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using imaging biomarkers to accelerate drug development and clinical trials.
    Pien HH; Fischman AJ; Thrall JH; Sorensen AG
    Drug Discov Today; 2005 Feb; 10(4):259-66. PubMed ID: 15708744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential surrogate endpoints in cancer research--some considerations and examples.
    Duffy SW; Treasure FP
    Pharm Stat; 2011; 10(1):34-9. PubMed ID: 20029937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers and proof of concept.
    Ferber G
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl C():35-40. PubMed ID: 12575486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.